Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Analyst II
UK
8+ years of experience
Louisa develops and delivers high-impact research regarding key trends and events in the pharmaceutical and biotechnology industries. She produces pipeline and marketed drug analyses, 10 year-patient/sales based forecasts and in-depth pre/post-conference opinion pieces.
She has a particular interest in analyzing the development of novel therapies from the early pre-clinical and clinical phases through final approval and marketing authorization.
Louisa joined Datamonitor Healthcare in June 2015, after completing a bachelor’s degree in Biochemistry and Pharmacology at the University of Bristol.Datamonitor Healthcare, Biomedtracker
By Louisa Joseph 29 Nov 2019
Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.
Topic Drug Pricing Market Access
Datamonitor Healthcare
By Louisa Joseph 10 May 2019
Join subject-matter experts from Datamonitor Healthcare as they use data and their industry experience to examine the challenges and opportunities brought about by recent global trends in market access. Learn how to navigate this complex terrain, as increasingly restrictive pricing and reimbursement policies are having an adverse effect on sales of launched and pipeline products across many global markets.
Topic Reimbursement
Datamonitor Healthcare
By Louisa Joseph 03 Jan 2019
The three urological cancers are undergoing tremendous changes in treatment practices as a result of new product launches and indication expansions.
Topic Cancer
Datamonitor Healthcare
By Louisa Joseph 22 Jun 2015
A US Food and Drug Administration (FDA) committee has endorsed Praluent (alirocumab; Sanofi/Regeneron) and Repatha (evolocumab; Amgen/Astellas) solely for high-risk hypercholesterol
Topic Vaccines
Scrip
07 Apr 2016
Scrip
25 Mar 2016
Scrip
18 Mar 2016
Scrip
10 Mar 2016
Scrip
12 Feb 2016
Scrip
12 Feb 2016
Scrip
10 Feb 2016
Scrip
10 Feb 2016
Scrip
09 Feb 2016
Scrip
03 Feb 2016
Scrip
12 Jan 2016
Scrip
07 Jan 2016
Scrip
21 Dec 2015
Scrip
30 Oct 2015
Scrip
30 Oct 2015
